CNS Pharmaceuticals, Inc.

The current price of CNSP is $4.01 — it has decreased by 7.60% since the previous close. Data as of Nov 5, 2026.

CNSP is down 12.83% over the past week, down 24.34% over the past month and down 41.20% over the past year. The price is below its 200-day moving average of $4.55.

Analysts' average 12-month price target for CNSP is $0.50, which implies 87.53% downside from the current price. Individual estimates range from $0.50 to $0.50.

Of the 1 analyst covering CNS Pharmaceuticals, Inc., 1 rates it a strong buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

CNS Pharmaceuticals, Inc. has a market capitalization of $5.86M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, CNS Pharmaceuticals, Inc. posted a loss of $0.38 per share against an estimate of -$0.24, missing expectations by 58.33%. Upcoming reports are listed in the earnings calendar.

CNS Pharmaceuticals, Inc. has not paid any dividends over the past year.

Companies most comparable to CNS Pharmaceuticals, Inc. include Pasithea Therapeutics Corp., Soligenix, Inc., Ensysce Biosciences, Inc., GRI Bio, Inc. and 60 Degrees Pharmaceuticals, Inc.

In the latest trading session CNSP moved between $4.00 and $4.11, a range of 2.74% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of CNS Pharmaceuticals, Inc. shows a strong sell rating today and a strong sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.

Over the past 52 weeks CNSP has traded between $1.90 and $10.54. The current price is 61.95% below its 52-week high.